409 related articles for article (PubMed ID: 17220417)
1. MexAB-OprM- and MexXY-overproducing mutants are very prevalent among clinical strains of Pseudomonas aeruginosa with reduced susceptibility to ticarcillin.
Hocquet D; Roussel-Delvallez M; Cavallo JD; Plésiat P
Antimicrob Agents Chemother; 2007 Apr; 51(4):1582-3. PubMed ID: 17220417
[No Abstract] [Full Text] [Related]
2. Relationship between antibiotic use and incidence of MexXY-OprM overproducers among clinical isolates of Pseudomonas aeruginosa.
Hocquet D; Muller A; Blanc K; Plésiat P; Talon D; Monnet DL; Bertrand X
Antimicrob Agents Chemother; 2008 Mar; 52(3):1173-5. PubMed ID: 18180356
[TBL] [Abstract][Full Text] [Related]
3. Role of MexAB-OprM in intrinsic resistance of Pseudomonas aeruginosa to temocillin and impact on the susceptibility of strains isolated from patients suffering from cystic fibrosis.
Buyck JM; Guénard S; Plésiat P; Tulkens PM; Van Bambeke F
J Antimicrob Chemother; 2012 Mar; 67(3):771-5. PubMed ID: 22218683
[No Abstract] [Full Text] [Related]
4. MexAB-OprM hyperexpression in NalC-type multidrug-resistant Pseudomonas aeruginosa: identification and characterization of the nalC gene encoding a repressor of PA3720-PA3719.
Cao L; Srikumar R; Poole K
Mol Microbiol; 2004 Sep; 53(5):1423-36. PubMed ID: 15387820
[TBL] [Abstract][Full Text] [Related]
5. Efflux pump inhibitors reduce the invasiveness of Pseudomonas aeruginosa.
Hirakata Y; Kondo A; Hoshino K; Yano H; Arai K; Hirotani A; Kunishima H; Yamamoto N; Hatta M; Kitagawa M; Kohno S; Kaku M
Int J Antimicrob Agents; 2009 Oct; 34(4):343-6. PubMed ID: 19615866
[TBL] [Abstract][Full Text] [Related]
6. In vivo impact of the MexAB-OprM efflux system on beta-lactam efficacy in an experimental model of Pseudomonas aeruginosa infection.
Boutoille D; Jacqueline C; Le Mabecque V; Potel G; Caillon J
Int J Antimicrob Agents; 2009 May; 33(5):417-20. PubMed ID: 19157801
[TBL] [Abstract][Full Text] [Related]
7. Bacteriostatic and bactericidal activities of eight fluoroquinolones against MexAB-OprM-overproducing clinical strains of Pseudomonas aeruginosa.
Dupont P; Hocquet D; Jeannot K; Chavanet P; Plésiat P
J Antimicrob Chemother; 2005 Apr; 55(4):518-22. PubMed ID: 15722391
[TBL] [Abstract][Full Text] [Related]
8. Measurement of Pseudomonas aeruginosa multidrug efflux pumps by quantitative real-time polymerase chain reaction.
Yoneda K; Chikumi H; Murata T; Gotoh N; Yamamoto H; Fujiwara H; Nishino T; Shimizu E
FEMS Microbiol Lett; 2005 Feb; 243(1):125-31. PubMed ID: 15668010
[TBL] [Abstract][Full Text] [Related]
9. Involvement of the MexXY-OprM efflux system in emergence of cefepime resistance in clinical strains of Pseudomonas aeruginosa.
Hocquet D; Nordmann P; El Garch F; Cabanne L; Plésiat P
Antimicrob Agents Chemother; 2006 Apr; 50(4):1347-51. PubMed ID: 16569851
[TBL] [Abstract][Full Text] [Related]
10. Multiple genotypic changes in hypersusceptible strains of Pseudomonas aeruginosa isolated from cystic fibrosis patients do not always correlate with the phenotype.
Wolter DJ; Black JA; Lister PD; Hanson ND
J Antimicrob Chemother; 2009 Aug; 64(2):294-300. PubMed ID: 19468029
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of the multidrug efflux pumps MexCD-OprJ and MexEF-OprN is associated with a reduction of type III secretion in Pseudomonas aeruginosa.
Linares JF; López JA; Camafeita E; Albar JP; Rojo F; Martínez JL
J Bacteriol; 2005 Feb; 187(4):1384-91. PubMed ID: 15687203
[TBL] [Abstract][Full Text] [Related]
12. Clinical strains of Pseudomonas aeruginosa overproducing MexAB-OprM and MexXY efflux pumps simultaneously.
Llanes C; Hocquet D; Vogne C; Benali-Baitich D; Neuwirth C; Plésiat P
Antimicrob Agents Chemother; 2004 May; 48(5):1797-802. PubMed ID: 15105137
[TBL] [Abstract][Full Text] [Related]
13. [The roles of active efflux system overexpression and outer membrane protein OprD deficiency or loss in carbapenem resistance of Pseudomonas aeruginosa].
Yi MY; Wang PY; Huang HJ; Liu YC
Zhonghua Yi Xue Za Zhi; 2006 Feb; 86(7):457-62. PubMed ID: 16677571
[TBL] [Abstract][Full Text] [Related]
14. Role of the MexXY multidrug efflux pump in moderate aminoglycoside resistance in Pseudomonas aeruginosa isolates from Pseudomonas mastitis.
Chuanchuen R; Wannaprasat W; Ajariyakhajorn K; Schweizer HP
Microbiol Immunol; 2008 Aug; 52(8):392-8. PubMed ID: 18667038
[TBL] [Abstract][Full Text] [Related]
15. Role of MexAB-OprM and MexXY-OprM efflux pumps and class 1 integrons in resistance to antibiotics in burn and Intensive Care Unit isolates of Pseudomonas aeruginosa.
Goli HR; Nahaei MR; Rezaee MA; Hasani A; Kafil HS; Aghazadeh M; Nikbakht M; Khalili Y
J Infect Public Health; 2018; 11(3):364-372. PubMed ID: 28993173
[TBL] [Abstract][Full Text] [Related]
16. The role of mex-gene products in antibiotic extrusion in Pseudomonas aeruginosa.
Yoneyama H; Ocaktan A; Tsuda M; Nakae T
Biochem Biophys Res Commun; 1997 Apr; 233(3):611-8. PubMed ID: 9168899
[TBL] [Abstract][Full Text] [Related]
17. [Two efflux systems expressed simultaneously in clinical Pseudomonas aeruginosa].
Hocquet D; Llanes C; Patry I; El Garch F; Plésiat P
Pathol Biol (Paris); 2004 Oct; 52(8):455-61. PubMed ID: 15465264
[TBL] [Abstract][Full Text] [Related]
18. MexXY-OprM efflux pump is required for antagonism of aminoglycosides by divalent cations in Pseudomonas aeruginosa.
Mao W; Warren MS; Lee A; Mistry A; Lomovskaya O
Antimicrob Agents Chemother; 2001 Jul; 45(7):2001-7. PubMed ID: 11408215
[TBL] [Abstract][Full Text] [Related]
19. Efflux-mediated resistance to tigecycline (GAR-936) in Pseudomonas aeruginosa PAO1.
Dean CR; Visalli MA; Projan SJ; Sum PE; Bradford PA
Antimicrob Agents Chemother; 2003 Mar; 47(3):972-8. PubMed ID: 12604529
[TBL] [Abstract][Full Text] [Related]
20. Resistance against antimicrobial peptides is independent of Escherichia coli AcrAB, Pseudomonas aeruginosa MexAB and Staphylococcus aureus NorA efflux pumps.
Rieg S; Huth A; Kalbacher H; Kern WV
Int J Antimicrob Agents; 2009 Feb; 33(2):174-6. PubMed ID: 18945595
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
